X
KEY PRODUCTS
Details:
Cannabinoid oral solution has received approval for the treatment of several neurological disorders. It functions by stimulating two receptors, cannabinoid receptor type 1 and type 2, within the endocannabinoid system, maintaining body's homeostatis.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Cophex 2024
Not Confirmed
Contact Supplier
Details:
The partnership aims to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas, within the next five years, both in India and other global markets.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: Akums Drugs & Pharmaceuticals Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 01, 2022
Details:
Paxzen (nirmatrelvir) is an oral protease inhibitor that is active against MPRO, a viral protease that plays an essential role in viral replication by cleaving the 2 viral polyproteins.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxzen
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
The current annual U.S. market for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg is approximately $30.0 million, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.
Lead Product(s): Prochlorperazine Maleate
Therapeutic Area: Psychiatry/Psychology Product Name: Prochlorperazine Maleate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: ANI Pharmaceuticals Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
The licences are applicable for both molnupiravir (API) and finished product in capsules form. It enables the company to launch the product within India as well as export to 104 other countries around the world, Biophore India Pharmaceuticals said in a statement.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: MK-4482
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Medicines Patent Pool
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 20, 2022
Details:
Paxlovid (Nirmatrelvir) is an oral protease inhibitor that is active against MPRO, a viral protease that plays an essential role in viral replication by cleaving the 2 viral polyproteins.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2022
Details:
Aviptadil is a synthetic form of vasoactive intestinal peptide (VIP) that, when administered, results in rapid clinical recovery in patients with severe SARS-COV-2 infection. Biophore has successfully developed aviptadil and is backward integrated with in-house API.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
Biophore has developed Aviptadil and is backward integrated with in-house API. The company has also informed that it will be commencing commercial production immediately after the approval is received.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
Favipiravir tablets will be sold under the brand name ‘Favizen’, is being manufactured at Zenara’s US FDA approved facility in Hyderabad.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Favipiravir is an antiviral agent that was initially discovered and developed because of its activity against another RNA (ribonucleic acid) virus, the influenza virus.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
